메뉴 건너뛰기




Volumn 6, Issue 4, 2009, Pages 362-367

Treatment of mild cognitive impairment (MCI)

Author keywords

APOE 4 genotype; Disease progression; Donepezil; Galantamine; Mild cognitive impairment; Rivastigmine; Rofecoxib

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; DONEPEZIL; GALANTAMINE; PIRACETAM; PLACEBO; RIVASTIGMINE; ROFECOXIB; TAU PROTEIN;

EID: 69149106814     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509788929282     Document Type: Conference Paper
Times cited : (52)

References (37)
  • 2
    • 0021207461 scopus 로고
    • Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
    • Glenner GG and Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3): 1131-1135 (1984).
    • (1984) Biochem Biophys Res Commun , vol.122 , Issue.3 , pp. 1131-1135
    • Glenner, G.G.1    Wong, C.W.2
  • 5
    • 16044373524 scopus 로고    scopus 로고
    • Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
    • Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870 (1996).
    • (1996) Nat Med , vol.2 , pp. 864-870
    • Scheuner, D.1    Eckman, C.2    Jensen, M.3    Song, X.4    Citron, M.5    Suzuki, N.6
  • 8
    • 14644416500 scopus 로고    scopus 로고
    • Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
    • Bennett DA, Schneider JA, Bienias JL, Evans DA and Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64: 834-841 (2005).
    • (2005) Neurology , vol.64 , pp. 834-841
    • Bennett, D.A.1    Schneider, J.A.2    Bienias, J.L.3    Evans, D.A.4    Wilson, R.S.5
  • 9
    • 4544335597 scopus 로고    scopus 로고
    • Mild cognitive impairment as a diagnostic entity
    • Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 182-194 (2004).
    • (2004) J Intern Med , vol.256 , pp. 182-194
    • Petersen, R.C.1
  • 10
    • 22844444303 scopus 로고    scopus 로고
    • Mild cognitive impairment as a clinical entity and treatment target
    • Petersen RC and Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62: 1160-1163 (2005).
    • (2005) Arch Neurol , vol.62 , pp. 1160-1163
    • Petersen, R.C.1    Morris, J.C.2
  • 15
    • 0030470196 scopus 로고    scopus 로고
    • The Alzheimer's Disease Assessment Scale
    • Mohs RC. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr 8: 195-203 (1996).
    • (1996) Int Psychogeriatr , vol.8 , pp. 195-203
    • Mohs, R.C.1
  • 19
    • 0025890255 scopus 로고
    • The Hopkins verbal learning test: Development of a new memory test with six equivalent forms
    • Brandt J. The Hopkins verbal learning test: Development of a new memory test with six equivalent forms. Clin Neurophychol 5: 125-142 (1991).
    • (1991) Clin Neurophychol , vol.5 , pp. 125-142
    • Brandt, J.1
  • 20
    • 33645558594 scopus 로고    scopus 로고
    • Clinical trials in mild cognitive impairment. lessons for the future
    • Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment. lessons for the future. J Neurol Neurosurg Psychiatry 77: 429-438 (2006).
    • (2006) J Neurol Neurosurg Psychiatry , vol.77 , pp. 429-438
    • Jelic, V.1    Kivipelto, M.2    Winblad, B.3
  • 21
    • 69149101850 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/
  • 24
    • 34248175274 scopus 로고    scopus 로고
    • Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment
    • DOI 10.1212/01.wnl.0000258542.58725.4c
    • Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC and Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68: 1588-1595 (2007). (Pubitemid 46717983)
    • (2007) Neurology , vol.68 , Issue.19 , pp. 1588-1595
    • Fleisher, A.S.1    Sowell, B.B.2    Taylor, C.3    Gamst, A.C.4    Petersen, R.C.5    Thal, L.J.6
  • 25
    • 33644791818 scopus 로고    scopus 로고
    • Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment
    • Gold M, Francke S, Nye JS, Goldstein HR, Fijal B, Truyen L, et al. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging 25(2): S521 (2004).
    • (2004) Neurobiol Aging , vol.25 , Issue.2
    • Gold, M.1    Francke, S.2    Nye, J.S.3    Goldstein, H.R.4    Fijal, B.5    Truyen, L.6
  • 26
    • 33645571173 scopus 로고    scopus 로고
    • Galantamine in the treatment of patients with mild cognitive impairment: Baseline demographics and psychometric testing results
    • Goldstein HR and Gold M. Galantamine in the treatment of patients with mild cognitive impairment: baseline demographics and psychometric testing results. Neurobiol Aging 25(2): S472-473 (2004).
    • (2004) Neurobiol Aging , vol.25 , Issue.2
    • Goldstein, H.R.1    Gold, M.2
  • 27
    • 33645433543 scopus 로고    scopus 로고
    • Galantamine in the treatment of patients with mild cognitive impairment: Effect of diagnostic type at baseline
    • Novak G. Galantamine in the treatment of patients with mild cognitive impairment: effect of diagnostic type at baseline. Neurobiol Aging 25(2): S474 (2004).
    • (2004) Neurobiol Aging , vol.25 , Issue.2
    • Novak, G.1
  • 28
    • 11144246343 scopus 로고    scopus 로고
    • Effect of galantamine on brain atrophy as assessed by MRI in patients with mild cognitive impairment
    • Scheltens P, Fox NC, Barkhof F and Gold M. Effect of galantamine on brain atrophy as assessed by MRI in patients with mild cognitive impairment. Neurobiol Aging 25 : S270-271 (2004).
    • (2004) Neurobiol Aging , vol.25
    • Scheltens, P.1    Fox, N.C.2    Barkhof, F.3    Gold, M.4
  • 29
    • 0027425211 scopus 로고
    • The clinical dementia rating (CDR): Current version and scoring rules
    • Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414 (1993).
    • (1993) Neurology , vol.43 , pp. 2412-2414
    • Morris, J.C.1
  • 32
    • 0015812367 scopus 로고
    • Selective reminding for analysis of memory and learning
    • Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12: 543-550 (1973).
    • (1973) J Verbal Learn Verbal Behav , vol.12 , pp. 543-550
    • Buschke, H.1
  • 37
    • 68849102065 scopus 로고    scopus 로고
    • Treatment response to rivastigmine in mild cognitive impairment: An enhanced statistical modeling approach
    • Submitted
    • Ferris S, Lane R, Sfikas N, Winblad B, Farlow M and Feldman HH. Treatment response to rivastigmine in mild cognitive impairment: An enhanced statistical modeling approach. Gend Med. Submitted (2009).
    • (2009) Gend Med
    • Ferris, S.1    Lane, R.2    Sfikas, N.3    Winblad, B.4    Farlow, M.5    Feldman, H.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.